The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Guido Marcucci

Division of Hematology-Oncology

Department of Medicine

and the Comprehensive Cancer Center

Ohio State University

USA

[email]@medctr.osu.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Hematology-Oncology, Department of Medicine, and the Comprehensive Cancer Center, Ohio State University, USA. 2003 - 2005
  • Department of Internal Medicine, Arthur G. James Cancer Hospital, Columbus, USA. 2000 - 2004
  • Department of Internal Medicine, Division of Hematology and Oncology, and Arthur G. James Cancer Hospital, The Ohio State University, USA. 2003

References

  1. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Marcucci, G., Mrózek, K., Bloomfield, C.D. Curr. Opin. Hematol. (2005) [Pubmed]
  2. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Marcucci, G., Stock, W., Dai, G., Klisovic, R.B., Liu, S., Klisovic, M.I., Blum, W., Kefauver, C., Sher, D.A., Green, M., Moran, M., Maharry, K., Novick, S., Bloomfield, C.D., Zwiebel, J.A., Larson, R.A., Grever, M.R., Chan, K.K., Byrd, J.C. J. Clin. Oncol. (2005) [Pubmed]
  3. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. Marcucci, G., Mrózek, K., Ruppert, A.S., Maharry, K., Kolitz, J.E., Moore, J.O., Mayer, R.J., Pettenati, M.J., Powell, B.L., Edwards, C.G., Sterling, L.J., Vardiman, J.W., Schiffer, C.A., Carroll, A.J., Larson, R.A., Bloomfield, C.D. J. Clin. Oncol. (2005) [Pubmed]
  4. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. Marcucci, G., Baldus, C.D., Ruppert, A.S., Radmacher, M.D., Mrózek, K., Whitman, S.P., Kolitz, J.E., Edwards, C.G., Vardiman, J.W., Powell, B.L., Baer, M.R., Moore, J.O., Perrotti, D., Caligiuri, M.A., Carroll, A.J., Larson, R.A., de la Chapelle, A., Bloomfield, C.D. J. Clin. Oncol. (2005) [Pubmed]
  5. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. Marcucci, G., Mrózek, K., Ruppert, A.S., Archer, K.J., Pettenati, M.J., Heerema, N.A., Carroll, A.J., Koduru, P.R., Kolitz, J.E., Sterling, L.J., Edwards, C.G., Anastasi, J., Larson, R.A., Bloomfield, C.D. J. Clin. Oncol. (2004) [Pubmed]
  6. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Marcucci, G., Byrd, J.C., Dai, G., Klisovic, M.I., Kourlas, P.J., Young, D.C., Cataland, S.R., Fisher, D.B., Lucas, D., Chan, K.K., Porcu, P., Lin, Z.P., Farag, S.F., Frankel, S.R., Zwiebel, J.A., Kraut, E.H., Balcerzak, S.P., Bloomfield, C.D., Grever, M.R., Caligiuri, M.A. Blood (2003) [Pubmed]
  7. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003. Marcucci, G., Perrotti, D., Caligiuri, M.A. Clin. Cancer Res. (2003) [Pubmed]
  8. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?. Marcucci, G., Caligiuri, M.A., Bloomfield, C.D. Eur. J. Haematol. (2003) [Pubmed]
  9. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Marcucci, G., Caligiuri, M.A., Bloomfield, C.D. Cancer Invest. (2000) [Pubmed]
 
WikiGenes - Universities